Stifel upgraded ChemoCentryx (NASDAQ:CCXI) to “buy” from “hold” and raised its price target to $31 from $26, citing a more favorable risk/reward for avacopan heading into a new PDUFA date. The stock closed at $14.05 on...
Cantor Fitzgerald initiated coverage of Jaguar Health (NASDAQ:JAGX) with an “overweight” rating and price target of $5. The stock closed at $1.49 on July 6. Jaguar Health is a commercial-stage pharmaceuticals company...
H.C. Wainwright initiated coverage of Axcella Health (NASDAQ:AXLA) with a “buy” rating and $14 price target. The stock closed at $3.97 on July 2. Axcella Health is a clinical-stage biotechnology company pioneering a new...
Cantor Fitzgerald launched coverage of Arcturus Therapeutics (NASDAQ:ARCT) with an “overweight” rating and $71 price target. The stock closed at $35.94 on July 1. Arcturus is leveraging its proprietary lipid-based...
Maxim Group initiated coverage of Stealth BioTherapeutics (NASDAQ:MITO) with a “buy” rating and price target of $3. The stock closed at $1.56 on June 30. Stealth is developing compounds that target mitochondrial...
Cantor Fitzgerald launched coverage of Sanara MedTech (NASDAQ:SMTI) with an “overweight” rating and a 12-month price target of $45. The stock closed at $36.66 on June 29. Sanara has built a portfolio of differentiated...
Research Capital initiated coverage of Perimeter Medical Imaging (TSXV:PINK) with a “speculative buy” rating and a 12-month price target of $4.90 (Canadian). The stock closed at $3.37 on June 28. Perimeter is a medical...
Cantor Fitzgerald initiated coverage of Lipocine (NASDAQ:LPCN) with an “overweight” rating and 12-month price target of $3. The stock closed at $1.36 on June 23. “We think Lipocine has multiple shots on goal across its...
Cantor Fitzgerald launched coverage of Evelo Biosciences (NASDAQ:EVLO) with an “overweight” rating and 12-month price target of $28. The stock closed at $16.08 on June 22. Evelo is developing oral therapies derived from...
Maxim Group initiated coverage of OSE Immunotherapeutics (NXT PA:OSE) with a “buy” rating and $22 price target. The stock closed at $13.56 on June 22. Analyst Naureen Quibria, Ph.D., writes that French-based OSE has a...